Home » Newsletters » BioWorld Science

BioWorld Science

June 29, 2012

View Archived Issues

Studies yield encouraging VRS-317 pharmacodynamic and safety data

Pfizer immunotherapeutic for inflammatory diseases shows promise in phase I trials

Epicutaneous patch for peanut allergy safe and effective in patients

Michael J. Fox Foundation extends support to biomarker research program

Insmed doses first patient in TARGET-NTM trial

Investigators in Israel design new mouse model of familial dysautonomia

Vorinostat in combination with bortezomib: Final results from VANTAGE trials

FDA approves Astellas drug for overactive bladder

Anthera updates phase III blisibimod plans

Gilead submits NDA for elvitegravir

Merrimack adds third arm to phase III trial in metastatic pancreatic cancer

FDA grants priority review to NDA for regorafenib

Novel PARP inhibitors developed in China

New formylpeptide receptor ligands patented by Allergan

Lilly presents novel MAP kinase p38 inhibitors

Research at Pfizer yields novel potential antibacterial drugs

New notum-directed antibodies may be useful to treat osteoporosis

Novel potential cancer immunotherapy designed in Korea

Synta reports on interim analysis of GALAXY trial

FDA accepts Shionogi NDA for review

Sanwa and Fuji submit application for hyperuricemia and gout treatment in Japan

Compugen shows potential of another B7/CD28-like protein target

SymBio opens enrollment in Japanese rigosertib trial

Astellas' Gonax approved in Japan

Vertex Pharmaceuticals announces final phase II data on VX-809/Kalydeco combination

Oxis Turbuhaler approved in Japan in different formulations

Eisai and Toyama Chemical obtain approval in Japan for rheumatoid arthritis drug

Japanese authorities approve Inlyta tablets

Mitsubishi Tanabe drug approved for type 2 diabetes

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 29, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 29, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...